TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional patent application and has advanced the build-out of its digital therapeutics strategy. The company is evolving its programs beyond the psychedelic molecule, into an eco-system…


Previous articlePT253 – Sean Hinton Ph.D. – Culture, Research Limitations, and Non-Medical Paths Forward
Next articleWesana Health Announces Definitive Agreement to Acquire PsyTech Inc.